Medigene AG Pre-Announces 2024 Financial Report Release
Medigene AG has announced the pre-release of its 2024 financial report, covering January 1 to December 31, 2024, set to be published online on July 31, 2025. This announcement aligns with financial reporting regulations and informs stakeholders of the timeline for detailed financial insights, which may influence investor decisions. Medigene, based in Germany, specializes in developing innovative immunotherapies for cancer treatment. Current market cap stands at €2.97M, with a year-to-date price performance of -79.50%.
Medigene ( (DE:MDG1) ) has provided an update.
Medigene AG has announced the pre-release of its financial report for the fiscal year 2024, which will cover the period from January 1, 2024, to December 31, 2024. The report is scheduled to be published online on July 31, 2025. This announcement is part of Medigene’s compliance with financial reporting regulations, and it provides stakeholders with a timeline for when they can expect detailed financial insights, potentially impacting investor decisions and market perceptions.
More about Medigene
Medigene AG is a biotechnology company based in Planegg/Martinsried, Germany. The company is involved in the development of innovative immunotherapies for the treatment of cancer, focusing on T cell receptor-modified T cells (TCR-Ts) and dendritic cell vaccines.
YTD Price Performance: -79.50%
Average Trading Volume: 7,981
Technical Sentiment Signal: Buy
Current Market Cap: €2.97M
For detailed information about MDG1 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- Last Minute Thought: Daniel Ives Weighs In on Tesla Stock Before Earnings Drop
- ‘So Long, Farewell,’ Says Investor About Apple Stock
- What Can David Goggins Teach You About Saving for Retirement?
Disclaimer & DisclosureReport an Issue
